Citius Oncology
CTOR
7 hedge funds and large institutions have $990K invested in Citius Oncology in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
913% more capital invested
Capital invested by funds: $97.7K → $990K (+$892K)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
0.17% more ownership
Funds ownership: 0.15% → 0.32% (+0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$125K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$42.9K |
| 3 |
AWA
Arkadios Wealth Advisors
Atlanta,
Georgia
|
+$13.6K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$9.82K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$5.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$40.1K |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$11.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $465K | +$125K | +106,970 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $249K | +$42.9K | +36,758 | +179% |
|
|
IA
3
IFP Advisors
Tampa,
Florida
| $96.6K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $67.1K | -$40.1K | -34,322 | -69% |
|
|
AWA
5
Arkadios Wealth Advisors
Atlanta,
Georgia
| $50.7K | +$13.6K | +11,666 | New |
|
|
6
Bank of America
Charlotte,
North Carolina
| $37.3K | +$9.82K | +8,411 | +5,257% |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $23.3K | +$5.84K | +5,000 | +1,429% |
|
|
YCM
8
Yakira Capital Management
Westport,
Connecticut
| – | -$11.2K | -11,999 | Closed |
|
CTOR Hedge Fund Activity: Q2 2025 in Review
7 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q2 2025, worth a combined $990K — up 913% from $97.7K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CTOR positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $125K. The largest seller was UBS Group, cutting an estimated $40.1K.
- 7 institutional investors held Citius Oncology (CTOR) as of Q2 2025, up from 6 in Q1 2025.
- Funds reported $990K of Citius Oncology stock for Q2 2025, up 913% quarter-over-quarter.
- 2 funds opened new Citius Oncology positions in Q2 2025 and 1 closed out, a net change of +1 holder.
- The largest Citius Oncology buyer in Q2 2025 was Jane Street, an estimated $125K added.
- The largest Citius Oncology seller in Q2 2025 was UBS Group, an estimated $40.1K sold.
Based on aggregated 13F filings for Q2 2025.